NEW YORK – Thermo Fisher Scientific said on Monday that it has acquired Belgium-based PharmaFluidics, the developer of the μPAC range of microchip-based chromatography columns.
Financial terms of the deal were not disclosed.
The µPAC portfolio of columns enhance liquid chromatography performance in biomarker, proteomics, and drug research and development applications, Thermo Fisher said. The columns enable improved separation performance and sensitivity, allowing for the identification of substantially more compounds in complex biological samples. The acquisition will complement Thermo Fisher's existing chromatography solutions to deliver extended analytical capabilities to researchers, Thermo Fisher said.
"[Liquid chromatography] is a key analytical technique across numerous applications, and its accuracy, reproducibility, and robustness is critical to the delivery of meaningful results," Kent Davidson, VP and general manager of Thermo Fisher's high-performance chromatography solutions, chromatography, and mass spectrometry business, said in a statement. "Columns are an essential part of these workflows, and the next-generation μPAC columns push this element to a new level through innovative pillar array technology, improving the quality of data."